LCG
NKTR icon

Lisanti Capital Growth’s Nektar Therapeutics NKTR Stock Holding History

Lisanti Capital Growth’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-470
Closed -$749K – 146
2018
Q1 		$749K Buy
+470
New +$606K 0.36% 101
2016
Q4 		– Sell
-838
Closed -$216K – 99
2016
Q3 		$216K Buy
+838
New +$216K 0.27% 94

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Lisanti Capital Growth's NKTR Position: Q2 2018 in Review

Lisanti Capital Growth sold out of Nektar Therapeutics (NKTR) in Q2 2018, closing a stake of 470 shares — an estimated $749K sold.

Lisanti Capital Growth first reported a position in NKTR in Q3 2016 and held it in 2 quarters. The position peaked at $749K in Q1 2018. 379 funds tracked by Wall St. Rank hold NKTR as of Q2 2018.

  • Lisanti Capital Growth reported no remaining Nektar Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Lisanti Capital Growth sold 470 Nektar Therapeutics shares in Q2 2018, an estimated $749K.
  • Lisanti Capital Growth first reported a position in Nektar Therapeutics in Q3 2016 and held it in 2 quarters.
  • Lisanti Capital Growth's Nektar Therapeutics position peaked at $749K in Q1 2018.
  • 379 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2018.

Based on Lisanti Capital Growth's 13F filing for Q2 2018, filed 13 Aug 2018.